New obesity pill enters human safety testing
NCT ID NCT06982131
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests an experimental oral drug called RO7795081 in 40 healthy overweight or obese adults. The main goals are to check safety and how the drug interacts with common statins (rosuvastatin and pitavastatin). Participants will receive the drug or a placebo in multiple phases, and researchers will monitor side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RO7795081 (also called CT-996 or RG6652)
What this could lead to
If successful, this could lead to a new oral medication for weight management that may be used alongside statins.
What could go wrong
This is a very early Phase 1 safety study with only 40 participants, so it may not show effectiveness or could reveal safety issues. Results may not apply to the general population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON Plc (LPRA) - Netherlands
RECRUITINGGroningen, 9728 NZ, Netherlands